82 related articles for article (PubMed ID: 19650002)
21. Targeting PCSK9 for the treatment of hypercholesterolemia.
Hedrick JA
Curr Opin Investig Drugs; 2009 Sep; 10(9):938-46. PubMed ID: 19705336
[TBL] [Abstract][Full Text] [Related]
22. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes.
Langhi C; Le May C; Kourimate S; Caron S; Staels B; Krempf M; Costet P; Cariou B
FEBS Lett; 2008 Mar; 582(6):949-55. PubMed ID: 18298956
[TBL] [Abstract][Full Text] [Related]
23. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
Lin J; Wang LY; Liu S; Wang XM; Yong Q; Yang Y; DU LP; Pan XD; Wang X; Jiang ZS
Chin Med J (Engl); 2010 May; 123(9):1133-8. PubMed ID: 20529551
[TBL] [Abstract][Full Text] [Related]
24. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system.
Poirier S; Prat A; Marcinkiewicz E; Paquin J; Chitramuthu BP; Baranowski D; Cadieux B; Bennett HP; Seidah NG
J Neurochem; 2006 Aug; 98(3):838-50. PubMed ID: 16893422
[TBL] [Abstract][Full Text] [Related]
25. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.
Cunningham D; Danley DE; Geoghegan KF; Griffor MC; Hawkins JL; Subashi TA; Varghese AH; Ammirati MJ; Culp JS; Hoth LR; Mansour MN; McGrath KM; Seddon AP; Shenolikar S; Stutzman-Engwall KJ; Warren LC; Xia D; Qiu X
Nat Struct Mol Biol; 2007 May; 14(5):413-9. PubMed ID: 17435765
[TBL] [Abstract][Full Text] [Related]
26. A PCSK9 variant and familial combined hyperlipidaemia.
Abifadel M; Bernier L; Dubuc G; Nuel G; Rabès JP; Bonneau J; Marques A; Marduel M; Devillers M; Munnich A; Erlich D; Varret M; Roy M; Davignon J; Boileau C
J Med Genet; 2008 Dec; 45(12):780-6. PubMed ID: 18708425
[TBL] [Abstract][Full Text] [Related]
27. A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction.
Kathiresan S;
N Engl J Med; 2008 May; 358(21):2299-300. PubMed ID: 18499582
[No Abstract] [Full Text] [Related]
28. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
Maxwell KN; Breslow JL
Proc Natl Acad Sci U S A; 2004 May; 101(18):7100-5. PubMed ID: 15118091
[TBL] [Abstract][Full Text] [Related]
29. Unravelling the functional significance of PCSK9.
Lambert G
Curr Opin Lipidol; 2007 Jun; 18(3):304-9. PubMed ID: 17495605
[TBL] [Abstract][Full Text] [Related]
30. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes.
Strøm TB; Holla ØL; Cameron J; Berge KE; Leren TP
Clin Chim Acta; 2010 Feb; 411(3-4):229-33. PubMed ID: 19917273
[TBL] [Abstract][Full Text] [Related]
31. Phase 3 data for PCSK9 inhibitor wows.
Sheridan C
Nat Biotechnol; 2013 Dec; 31(12):1057-8. PubMed ID: 24316621
[No Abstract] [Full Text] [Related]
32. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities.
Mbikay M; Sirois F; Mayne J; Wang GS; Chen A; Dewpura T; Prat A; Seidah NG; Chretien M; Scott FW
FEBS Lett; 2010 Feb; 584(4):701-6. PubMed ID: 20026049
[TBL] [Abstract][Full Text] [Related]
33. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
Abifadel M; Rabès JP; Devillers M; Munnich A; Erlich D; Junien C; Varret M; Boileau C
Hum Mutat; 2009 Apr; 30(4):520-9. PubMed ID: 19191301
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.
Maxwell KN; Fisher EA; Breslow JL
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2069-74. PubMed ID: 15677715
[TBL] [Abstract][Full Text] [Related]
35. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene.
Abifadel M; Rabès JP; Jambart S; Halaby G; Gannagé-Yared MH; Sarkis A; Beaino G; Varret M; Salem N; Corbani S; Aydénian H; Junien C; Munnich A; Boileau C
Hum Mutat; 2009 Jul; 30(7):E682-91. PubMed ID: 19319977
[TBL] [Abstract][Full Text] [Related]
36. Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage.
Cameron J; Holla ØL; Laerdahl JK; Kulseth MA; Berge KE; Leren TP
Atherosclerosis; 2009 Mar; 203(1):161-5. PubMed ID: 19022446
[TBL] [Abstract][Full Text] [Related]
37. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Abifadel M; Varret M; Rabès JP; Allard D; Ouguerram K; Devillers M; Cruaud C; Benjannet S; Wickham L; Erlich D; Derré A; Villéger L; Farnier M; Beucler I; Bruckert E; Chambaz J; Chanu B; Lecerf JM; Luc G; Moulin P; Weissenbach J; Prat A; Krempf M; Junien C; Seidah NG; Boileau C
Nat Genet; 2003 Jun; 34(2):154-6. PubMed ID: 12730697
[TBL] [Abstract][Full Text] [Related]
38. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
39. Of PCSK9, cholesterol homeostasis and parasitic infections: possible survival benefits of loss-of-function PCSK9 genetic polymorphisms.
Mbikay M; Mayne J; Seidah NG; Chrétien M
Med Hypotheses; 2007; 69(5):1010-7. PubMed ID: 17502126
[TBL] [Abstract][Full Text] [Related]
40. Genetic susceptibility to myocardial infarction and coronary artery disease.
Topol EJ; Smith J; Plow EF; Wang QK
Hum Mol Genet; 2006 Oct; 15 Spec No 2():R117-23. PubMed ID: 16987874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
